Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606
Completed · Phase 1
Conditions studied: Healthy Subjects
In brief
This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.
Key facts
- Study ID
- NCT00757341
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 6
- Starts
- 2008-12-01
- Expected to finish
- 2008-12-01
- Last updated by the study team
- 2009-04-27
Who can join
Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.
Where it is running
- Study site — Tacoma, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.